Clinical trials: Hepatic Tumors
Cancer, Lung, Cancer Liver
PixelShine vs. Iterative Reconstruction (IR) Processing of CT Images
This study will compare the quality of CT images acquired with very low-dose radiation and processed with commercially available software vs. PixelShine processed images.
- Conditions
- Cancer, Lung, Cancer Liver, X-rays; Effects
- Trial name
- NCT03033615
- Testing
- PixelShine, Conventional processing
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AlgoMedica, Inc.
HCC, Hepatocellular Carcinoma
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have…
- Trial name
- NCT06984718
- Testing
- AK104+lenvatinib, lenvatinib
- Volunteers
- 120 people
- Sponsor
- Akeso
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
- Trial name
- NCT07859735
- Testing
- Velzatinib
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Cancer
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with…
- Trial name
- READ90Y (NCT03516695)
- Testing
- TheraSphere®
- Where
- 8 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma (HCC)
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
This is a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CT-01, administered either as monotherapy or…
- Trial name
- NCT06994572
- Testing
- CT-01, EVEROLIMUS
- Volunteers
- 141 people
- Sponsor
- Captor Therapeutics S.A.
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of…
- Trial name
- NCT03713593
- Testing
- lenvatinib, pembrolizumab
- Where
- 172 sites in United States, Australia and 19 more
- Volunteers
- 794 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no…
- Trial name
- IMbrave150 (NCT03434379)
- Testing
- Atezolizumab, Bevacizumab, Sorafenib
- Where
- 119 sites in United States, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Hoffmann-La Roche
Primary Hepatocellular Carcinoma
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA)…
- Trial name
- DC-TC (NCT01828762)
- Testing
- DC-TC+GM-CSF
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai AbelZeta Ltd.
Liver Neoplasms, Adenoma
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years.
- Conditions
- Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
- Trial name
- NCT01043523
- Testing
- Gadoxetic Acid Disodium (Eovist, BAY86-4873)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.
- Trial name
- NCT01171651
- Testing
- JX-594, Sorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Jennerex Biotherapeutics
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Hepatic Carcinoma
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.
- Trial name
- NCT01760616
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 790 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Systemic Fungal Infections
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with…
- Trial name
- MYCOS (NCT01686607)
- Testing
- Parenteral micafungin application, Other parenteral antifungal drugs
- Where
- 6 sites in United States
- Volunteers
- 40,110 people
- Sponsor
- Astellas Pharma Europe B.V.
Carcinoma, Hepatocellular
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Nexavar for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT01411436
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 1,637 people
- Sponsor
- Bayer
Liver Carcinoma
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.
- Trial name
- NCT00791544
- Testing
- AVE1642, sorafenib, erlotinib
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Sanofi
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Liver Biopsy
Identification of Liver Tumours Using BIP - Biopsy System
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP…
- Trial name
- NCT02620228
- Testing
- BIP Biopsy System
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Injeq Ltd
Carcinoma, Hepatocellular
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
- Trial name
- NCT01246986
- Testing
- LY2157299, Sorafenib, Ramucirumab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company